# References

Warrick, Joshua I., et al. "International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer. Working Group 4: Molecular Subtypes of Bladder Cancer—Principles of Classification and Emerging Clinical Utility." *The American journal of surgical pathology* 48.1 (2024): e32-e42.

Babjuk, Marko, et al. "European Association of Urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)." *European urology* 81.1 (2022): 75-94.

Aveta, Achille, et al. "The impact of meat intake on bladder cancer incidence: is it really a relevant risk?." *Cancers* 14.19 (2022): 4775.

Ibrahim, Nurul Khalida, et al. "Detection of cancer mutations by urine liquid biopsy as a potential tool in the clinical management of bladder cancer patients." *Cancers* 14.4 (2022): 969.

Gravas, Stavros, et al. "Summary paper on the 2023 European Association of Urology guidelines on the management of non-neurogenic male lower urinary tract symptoms." *European urology* 84.2 (2023): 207-222.

Mohanty, Sambit K., et al. "Precision medicine in bladder cancer: present challenges and future directions." *Journal of Personalized Medicine* 13.5 (2023): 756.

Zhang, Yongzhen, et al. "Identification of core genes and key pathways via integrated analysis of gene expression and DNA methylation profiles in bladder cancer." *Medical science monitor: international medical journal of experimental and clinical research* 24 (2018): 3024.

Bazargan, Sarah, et al. "Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer." *Frontiers in Immunology* 14 (2023): 1275375.

Babjuk, Marko, et al. "European Association of Urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)." *European urology* 81.1 (2022): 75-94.

Claps, Francesco, et al. "BCG-unresponsive non-muscle-invasive bladder cancer: current treatment landscape and novel emerging molecular targets." *International journal of molecular sciences* 24.16 (2023): 12596.

Tomko, Andrea M., Erin G. Whynot, and Denis J. Dupré. "Anti-cancer properties of cannflavin A and potential synergistic effects with gemcitabine, cisplatin, and cannabinoids in bladder cancer." *Journal of Cannabis Research* 4.1 (2022): 41.

Li, Changjiu, et al. "The oncogenic functions of SPARCL1 in bladder cancer." *Journal of Cellular and Molecular Medicine* 28.22 (2024): e70196.

Chen, Wujun, et al. "ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential." *Frontiers in Immunology* 13 (2022): 1040669.

Chen, Ji-Qing, et al. "Immune profiles and DNA methylation alterations related with non-muscle-invasive bladder cancer outcomes." *Clinical Epigenetics* 14.1 (2022): 14.

ŞEN, Selda, et al. "The effect of spinal and general anesthesia on metastatic lymph node flow in bladder cancer surgery: A pilot study." *Agri: Journal of the Turkish Society of Algology/Tu? rk Algoloji (Ag? r?) Derneg? i'nin Yayin Organidir* 33.3 (2021).

Ferlay, Jacques, et al.[[1]](#endnote-0) "Cancer statistics for the year 2020: An overview." *International journal of cancer* 149.4 (2021): 778-789.

1. Aveta, Achille, et al. "The impact of meat intake on bladder cancer incidence: is it really a relevant risk?." Cancers 14.19 (2022): 4775.

   Babjuk, Marko, et al. "European Association of Urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)." European urology 81.1 (2022): 75-94.

   Tran, Linda, et al. "Advances in bladder cancer biology and therapy." Nature Reviews Cancer 21.2 (2021): 104-121.

   Ferro, Matteo, et al. "Impact of age on outcomes of patients with pure carcinoma in situ of the bladder: multi-institutional cohort analysis." Clinical Genitourinary Cancer 20.2 (2022): e166-e172.

   Jubber, Ibrahim, et al. "Epidemiology of bladder cancer in 2023: a systematic review of risk factors." European urology 84.2 (2023): 176-190.

   Zhao, Xiaohu, Yuanli Wang, and Chaozhao Liang. "Cigarette smoking and risk of bladder cancer: a dose–response meta-analysis." International urology and nephrology 54.6 (2022): 1169-1185.

   Huan, Jianya, et al. "Emerging roles for mammalian target of rapamycin (mTOR) complexes in bladder cancer progression and therapy." Cancers 14.6 (2022): 1555.

   Goswami, Ritabrita, et al. "Nuclear localization signal-tagged systems: Relevant nuclear import principles in the context of current therapeutic design." Chemical Society Reviews (2024).

   Zuo, Mingshun, et al. "Sulforaphane and bladder cancer: a potential novel antitumor compound." Frontiers in Pharmacology 14 (2023): 1254236.

   Babjuk, Marko, et al. "European Association of Urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)." European urology 81.1 (2022): 75-94.

   Jubber, Ibrahim, et al. "Epidemiology of bladder cancer in 2023: a systematic review of risk factors." European urology 84.2 (2023): 176-190.

   Adrien, Oriane, et al. "Prescribing cascades with recommendations to prevent or reverse them: a systematic review." Drugs & Aging 40.12 (2023): 1085-1100.

   Messina, Emanuele, et al. "Seeing is believing: state of the art imaging of bladder cancer." Seminars in Radiation Oncology. Vol. 33. No. 1. WB Saunders, 2023.

   Hu, Xinzi, Guangzhi Li, and Song Wu. "Advances in diagnosis and therapy for bladder cancer." Cancers 14.13 (2022): 3181.

   Bourlotos, Georgia, et al. "BCG induced lower urinary tract symptoms during treatment for NMIBC—Mechanisms and management strategies." Frontiers in Neuroscience 17 (2024): 1327053.

   Ascione, Claudia Maria, et al. "Role of FGFR3 in bladder cancer: Treatment landscape and future challenges." Cancer Treatment Reviews 115 (2023): 102530.

   Lai, Lillian Y., et al. "Narrow band imaging versus white light cystoscopy alone for transurethral resection of non‐muscle invasive bladder cancer." *Cochrane Database of Systematic Reviews* 4 (2022).

   Veeratterapillay, Rajan, et al. "Time to turn on the blue lights: a systematic review and meta-analysis of photodynamic diagnosis for bladder cancer." *European urology open science* 31 (2021): 17-27.

   Zheng, Rui, et al. "LncRNA BCCE4 genetically enhances the PD‐L1/PD‐1 interaction in smoking‐related bladder cancer by modulating miR‐328‐3p‐USP18 signaling." *Advanced Science* 10.30 (2023): 2303473.

   Ma, Wenchao, et al. "Can smoking cause differences in urine microbiome in male patients with bladder cancer? A retrospective study." *Frontiers in oncology* 11 (2021): 677605.

   Gravas, Stavros, et al. "Summary paper on the 2023 European Association of Urology guidelines on the management of non-neurogenic male lower urinary tract symptoms." *European urology* 84.2 (2023): 207-222.

   Powles, Thomas, et al. "Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆." *Annals of Oncology* 33.3 (2022): 244-258.

   Propper, David J., and Frances R. Balkwill. "Harnessing cytokines and chemokines for cancer therapy." *Nature reviews Clinical oncology* 19.4 (2022): 237-253.

   Bazargan, Sarah, et al. "Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer." *Frontiers in Immunology* 14 (2023): 1275375.

   Flores Monar, Gabriela Vanessa, et al. "Molecular markers for bladder cancer screening: an insight into bladder cancer and FDA-approved biomarkers." *International Journal of Molecular Sciences* 24.18 (2023): 14374.

   Balar, Arjun V., et al. "Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study." *The Lancet Oncology* 22.7 (2021): 919-930.

   Sfakianos, John P., et al. "Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer." *Urologic Oncology: Seminars and Original Investigations*. Vol. 39. No. 2. Elsevier, 2021.

   Ashrafizadeh, Milad, et al. "(Nano) platforms in bladder cancer therapy: Challenges and opportunities." *Bioengineering & translational medicine* 8.1 (2023): e10353.

   van Puffelen, Jelmer H., et al. "Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer." *Nature Reviews Urology* 17.9 (2020): 513-525.

   Lamm, Donald L., and Alvaro Morales. "A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatment." *Vaccine* 39.50 (2021): 7308-7318.

   Dyrskjøt, Lars, et al. "Bladder cancer." *Nature Reviews Disease Primers* 9.1 (2023): 58.

   Tran, Linda, et al. "Advances in bladder cancer biology and therapy." *Nature Reviews Cancer* 21.2 (2021): 104-121.

   Lobo, Niyati, et al. "100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19." *Nature Reviews Urology* 18.10 (2021): 611-622.

   Holzbeierlein, Jeffrey M., et al. "Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment." *Journal of Urology* (2024): 10-1097.

   Sood, Rajeev, et al. "A prospective comparative study to assess the efficacy and tolerability of 2 different doses of intravesical bacillus Calmette-Guerin (BCG) in patients with non–muscle-invasive bladder cancer." *Urologic Oncology: Seminars and Original Investigations*. Vol. 38. No. 5. Elsevier, 2020.

   Flaig, Thomas W., et al. "Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology." *Journal of the National Comprehensive Cancer Network* 18.3 (2020): 329-354.

   Subiela, José Daniel, et al. "Carcinoma in situ of the urinary bladder: a systematic review of current knowledge regarding detection, treatment, and outcomes." *European Urology Focus* 6.4 (2020): 674-682.

   Koch, George E., Woodson W. Smelser, and Sam S. Chang. "Side effects of intravesical BCG and chemotherapy for bladder cancer: what they are and how to manage them." *Urology* 149 (2021): 11-20.

   Tappero, Stefano, et al. "Ileal conduit versus orthotopic neobladder urinary diversion in robot-assisted radical cystectomy: results from a multi-institutional series." *European Urology Open Science* 50 (2023): 47-56.

   Kamoun, Aurelie, et al. "A consensus molecular classification of muscle-invasive bladder cancer." *European urology* 77.4 (2020): 420-433.

   Babjuk, Marko, et al. "European Association of Urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)." *European urology* 81.1 (2022): 75-94.

   Gontero, Paolo, et al. "European association of Urology guidelines on non–muscle-invasive bladder cancer (TaT1 and Carcinoma In Situ)—A summary of the 2024 guidelines update." *European Urology* (2024).

   Hurle, Rodolfo, et al. "Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non–muscle-invasive bladder cancer after BCG failure." *Urologic Oncology: Seminars and Original Investigations*. Vol. 39. No. 3. Elsevier, 2021.

   Messing, Edward M., et al. "Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non–muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial." *Jama* 319.18 (2018): 1880-1888.

   Zeng, Siyuan, et al. "Chemoresistance in pancreatic cancer." *International journal of molecular sciences* 20.18 (2019): 4504.

   Steinberg, Ryan L., et al. "Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer." *The Journal of urology* 203.5 (2020): 902-909.

   Karavana, Sinem Yaprak, et al. "Gemcitabine hydrochloride microspheres used for intravesical treatment of superficial bladder cancer: a comprehensive in vitro/ex vivo/in vivo evaluation." *Drug design, development and therapy* (2018): 1959-1975.

   Abou Chaaya, Carla, et al. "Comparing efficacy and safety of in-house gemcitabine to mitomycin for bladder instillation in intermediate-risk NMIBC." *The French Journal of Urology* 34.13 (2024): 102699.

   Tomko, Andrea M., Erin G. Whynot, and Denis J. Dupré. "Anti-cancer properties of cannflavin A and potential synergistic effects with gemcitabine, cisplatin, and cannabinoids in bladder cancer." *Journal of Cannabis Research* 4.1 (2022): 41.

   Ben-David, Reuben, et al. "Induction and maintenance of sequential intravesical gemcitabine/docetaxel for intermediate and high-risk non-muscle invasive bladder cancer with different dosage protocols." *World Journal of Urology* 42.1 (2024): 315.

   Autenrieth, M. E., et al. "Intravesical radioimmunotherapy of carcinoma in situ of the urinary bladder after BCG failure." *Der Urologe* 56 (2017): 40-43. [↑](#endnote-ref-0)